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Research
The Use of Fluorescence Technology versus Visual
and Tactile Examination in the Detection of Oral
Lesions: A Pilot Study
Hadeel M. Ayoub, BSDH, MSDH; Tara L. Newcomb, BSDH, MS; Gayle B. McCombs, RDH, MS;
Marshall Bonnie, DDS

Introduction

Abstract

The importance of oral cancer
screening is widely documented in
the literature.1 Oral cancer prevalence continues to increase every
year, with an estimated 41,380
new oral cancer cases in 2013.2
Over 7,890 of those cases are expected to include a negative prognosis or death from the disease.2 In
the U.S. alone there are 275,193
cases living with oral cancer, and
the average 5 year survival rate
for those people is 62.2%.2 Late
detection of oral cancer (when the
cancer has reached stage III or IV)
is a contributing factor in high morbidity and mortality rates.3 Several
factors contribute to the late detection of cancerous lesions such
as not conducting a comprehensive
intraoral and extraoral oral cancer
screening and the difficulty to detect early precancerous and cancerous lesions. Because of the difficulty in oral cancer early detection,
lesions are often detected in advanced stages and show evidence
of invasion and metastasis, which
results in disfigurement from invasive treatments. Late diagnosis of
the disease is unfortunate because
oral cancer patients have an 80
to 90% survival rate when lesions
are detected early (premalignant
lesions, or when the lesion is on
stage I) (Table I).2 Early diagnosis
of oral cancer results in minimally invasive procedures and better
prognosis.4 Premalignant lesions,
stage I and II oral cancers can remain undetected until symptoms
present clinically.4,5 According to
the National Cancer Institute, the

Purpose: This study compared the effectiveness of the VELscope®
Vx versus visual and tactile intraoral examination in detecting oral
lesions in an adult, high risk population.
Methods: The pilot study compared the intra oral findings between 2 examination types. The sample was comprised of 30 participants who were addicted to either cigarettes or a dual addiction (cigarettes plus hookah). High risk population was defined as
males who were current cigarette smokers or had a dual addiction.
Two trained and experienced licensed dental hygienists conducted
all examinations. Throughout the study, all visual and tactile intraoral examinations were conducted first by one dental hygienist
first, followed by the VELscope® Vx fluorescence examinations by
the second dental hygienist. All subjects received an inspection
of the lips, labial and buccal mucosa, floor of the mouth, dorsal,
ventral and lateral sides of the tongue, hard and soft palate, and
visual inspection of the oropharynx and uvula. Both evaluations
took place in 1 visit in the Dental Hygiene Research Center at Old
Dominion University and external sites. All participants received
oral cancer screening information, recommendations, referrals for
tobacco cessation programs and brochures on the 2 types of examinations conducted.
Results: Participants were considered high risk based on demographics (current smokers and mostly males). Neither visual and
tactile intraoral examination nor the VELscope® Vx examination
showed positive lesions. No lesions were detected; therefore, no
referrals were made. Data indicated the duration of tobacco use
was significantly higher in cigarette smokers (14.1 years) than
dual addiction smokers (5 years) (p>0.005). The average numbers of cigarettes smoked per day were 13.5 compared to 14.2
cigarettes for dual addiction smokers.
Conclusion: Results from this study suggest the visual and tactile
intraoral examination produced comparative results to the VELscope® Vx examination. Findings from this study support that the
VELscope® Vx is still considered an adjunct technology and cannot
be used exclusively for oral cancer screening.
Keywords: oral cancer, VELscope® Vx, dual addiction, oral potentially malignant lesions
This study supports the NDHRA priority area, Clinical Dental Hygiene Care: Investigate how dental hygienists use emerging science to reduce risk in susceptible patients (risk reduction strategies).
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Table I: Five-Year Oral Cancer Relative Survival Rate, Based on the Data from the National Cancer Institute, SEER Program, NIH
Stage

Site

I

II

III

IV

Lip

96.3%

82.7%

56.7%

48.1%

Tongue

70.7%

58.6%

47.3%

36.7%

Floor of the mouth

72.5%

60.1%

35.8%

29.7%

Gingiva and other
soft tissue

80.9%

62.2%

45.1%

40.0%

highest survival rate in early cancerous lesions
is for stage I lip cancer (96.3%), whereas the
lowest survival rate is for stage II tongue cancer
(58.6%).5 According to Healthy People 2020, detecting oral and pharyngeal cancers at the earliest stages (stage I and II) is a critical objective.6
In 2007, 32.5% of the oral and pharyngeal cancers detected were at their earliest stages.6 This
suggests that by the year 2020 the percentage of
oral and pharyngeal cancers diagnosed at early
stages should reach a 10% improvement.6 Since
oral cancer is mostly detected in late stages, almost one-half of oral cancer survivors are at risk
of developing local or regional recurrence and/
or distant metastasis.7 In addition, up to 90%
of treatment failures are for local and regional
recurrences.7
Early cancer or premalignant lesions can mimic benign lesions, appearing as asymptomatic,
white lesions (Leukoplakia) or red lesions (Erythroplakia). The surgical removal of leukoplakia is
only obligatory when the dysplasia is diagnosed
as moderate to severe. On the other hand, erythroplakia transforms to squamous cell carcinoma
or carcinoma in situ in 90% of the cases. However, some of the red and white lesions do not
always progress into malignant lesions.3,5 Safe,
cost effective technologies could improve diagnosis and early treatment, and would decrease
mortality rates while minimizing disfigurement.4
Research shows long-term effects of late diagnosis, including aggressive treatments and disfigurement, xerostomia, chewing and swallowing
difficulties, dental caries, and depression.1 Currently, the only accurate differential diagnosis is
through scalpel biopsy and histologic examination which are gold standard diagnosing procedures but severely invasive and expensive.3
Intraoral and extraoral visual and tactile examination is still the standard of care for oral cancer screening. Traditional oral cancer screening
includes taking an updated medical and dental
history to identify risk factors including tobacco
use (smoking or smokeless), alcohol consump64

tion, HPV infection, frequent exposure to ultraviolet light, poor nutrition and genetic factors.8 The
National Institute of Dental and Craniofacial Research developed an oral cancer screening protocol for the clinicians to use with every patient
as a part of the regular periodic appointment.8
The examination consists of 2 parts: extraoral
examination, intraoral soft tissue examination.
The extraoral examination includes visual and
palpatory inspection of the face, ears, neck and
the regional lymph nodes areas. Comprehensive
intraoral soft tissue examination requires a visual
and palpatory evaluation of the lips, labial mucosa, right and left buccal mucosa, gingiva, the
dorsal, ventral and lateral sides of the tongue,
the floor of the mouth, the hard and soft palate,
and the oropharynx and uvula. Practicing dental
hygienists and dentists are using mixed oral cancer screening protocols or none at all.8 There is
little guidance for dental hygienists or dentists
who are interested in improving their oral cancer detection because of the lack of standardization regarding the benefits of traditional oral
cancer screenings versus optical or technologybased imaging in early detection of oral cancer.
The similarity in appearance between benign and
premalignant oral lesions makes it difficult to rely
on the traditional oral cancer screening.
The Oral Cancer Foundation supports research
and development of technology-based techniques
and devices that are non-invasive to detect initial,
asymptomatic cell change as soon as possible.9
Technology-based devices capabilities include increased ability by oral health care professionals
to identify, contrast (abnormal versus abnormal),
and monitor submucosal and dysplastic changes
not visible during a visual oral cancer screening.
While these screening devices do not differentiate between malignant and benign lesions, when
used in conjunction with a traditional oral cancer
screening, they may assist oral health professionals in recognizing abnormal lesions or oral
potentially malignant lesions at earlier stages.1
Oral cancer screening tools such as the VEL-

The Journal of Dental Hygiene

Vol. 89 • No. 1 • February 2015

Table II: Oral Cancer Screening Devices
Product Name

Company

Dispensing Method

Unique Features

LED Dental Inc.

• Lighted device
• Emits blue-light
• Clinician views oral cavity through
the VELscope® Vx lens

• Cordless, portable
• Digital camera attachment
• Uses blue light to simulate natural
fluorescence
• No solutions used

Identafi®

DentalEZ group
StarDental

• Hand-held mirror emits 3 different type of light modes
• Safe blue light, white light and
amber light into the oral cavity
• Clinician views tissue discoloration using the three modes

• Cordless, portable
• Ability to examine tissue vasculature
• No solutions used

ViziLite® Plus

ZILA
Pharmaceutical
Inc.

• Uses low energy blue-white light
source
• Clinician activates the light source
by bending the vial container then
insert it to a holder

• Cordless, portable
• Requires, with Microlux/DL, a
pre-rinse for 30 seconds
• Can be used in conjunction with
TBlue (Tuludine blue-based dye)

MicroluxTM/DL

AdDent
Incorporated

• Produces blue-white LED light
source
• Clinician views white lesions

• Cordless, portable device
• Requires, with ViziLite® Plus, a
pre-rinse for 60 seconds

VELscope® Vx

scope® Vx, LED (Dental Inc, Burnaby, BC, Canada); Identafi® (StarDental, Lancaster, PA);
ViziLite® Plus with TBlue, ZILATM (Fort Collins,
Colo.); and the MicroluxTM/DL, (AdDental Inc,
Danbury, Conn.), are technology-based devices
available for use in private practice and public
health settings (Table II). Technology-based devices include hand-held operating systems that
use several chemiluminescence, blue-white LED
and autofluorescence to penetrate epithelial tissue; light based systems enhance the visual inspection of intraoral tissues and help distinguish
healthy areas versus oral potentially malignant
lesions occurring at the submucosal layers and
therefore not readily visible to the naked eye.
Each device has individual defining features
aimed to detect submucosal cell change or rapid
destructive cell mutation and determine whether
the lesion has metastasized to underlying connective tissue. This is a limitation of visual oral
cancer screening examinations. More research is
needed to support the use of technology-based
screening tools for early detection of oral cancer
in the general (low-risk) populations.10-13 Also,
current literature does not support exclusive use
of technology-based screening protocols in reducing mortality rates in smokers.12
VELscope® Vx is a non-magnifying, wide-field
imaging device. The original VELscope® was primarily approved by the FDA on April, 2006 to
be used as an adjunct oral mucosal examination
device. In November 2010, the newer genera-

tion VELscope® Vx was
approved by the FDA
for the same purposes
(Figure 1).14 The new
VELscope® Vx is easier to carry, allows for
broader intramural imaging and is cordless
(utilizing a 12 hour
battery). It does not
require a dimmed light
and can be used under incandescent light.
VELscope® Vx has a
higher intensity for a
better
visualization;
an external camera attachment was added
to facilitate a photo
documentation of suspicious lesions during
exams.
Researchers
choose the new generation VELscope Vx
because of these advances in the technology and to provide
research on the most
current device.

Figure 1: Visual Enhanced Lesion Scope
(VELscope® Vx)

Source: picture provided by

The Identafi® system LED dental Inc., the manuuses 3 light modes: facturer of the VELscope® Vx
a white light mode, a
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fluorescent violet mode and an amber reflectance
mode. Identafi® fluorescent light makes an abnormal lesion appear dark brown or black, and
healthy tissue reflect as blue fluorescence areas.
ViziLite® Plus with TBlue system uses a low energy blue white light source, which requires a 30
second acetic acid pre-rinse that dehydrates the
tissue. Normal tissue appears healthy pink, while
abnormal tissue appears as acetowhite in color.
MicroluxTM/DL system uses a blue-white LED
light source. It uses a bright light, illumination
technology, but is currently recognized specifically for better discovery of keratotic lesions that
might not be discovered using the chair-side
light. Abnormal tissue will appear as acetowhite,
while normal tissue will appear as a healthy pink
in color. The VELscope® Vx elicits a green, homogeneous fluorescence of normal tissue (Figure 2).
A reduction in the green fluorescence indicates
abnormal tissue.15 However, the abnormality may
indicate either pathological conditions (such as
precancerous or cancerous lesions) or variation
from normal structures (such as Linea alba in the
buccal mucosa).
Unlike other types of light-based systems, the
VELscope® Vx does not require a pre-rinse and
does not contain a lesion-marking solution. The
VELscope® Vx allows for the adaptation of a digital camera, which aids in monitoring and accessing submucosal parameters of suspicious lesions.
In addition to the recommendations from the
Oral Cancer Foundation,9 Marzouki et al16 concluded that “the VELscope may add sensitivity to
the clinical examination and be a useful adjunct
in high-risk patients.”
Under the VELscope® Vx light dysplastic and
malignant cells will appear as a dark area of abnormality as they interrupt and cause a loss of
fluorescence.13 Preliminary studies showed that
the sensitivity and specificity of the VELscope®
Vx were both higher than 90%.10,11,16 The evidence support the effectiveness of the VELscope®
Vx in identifying extended borders of known lesions but there is not enough evidence to support
or refute its effectiveness in detecting early oral
cancer lesions in general populations.10,11
VELscope® Vx and other screening devices
have high false positive rates.10 The positive and
negative predictive values of the VELscope® Vx
were found to be around 42 and 98%, respectively.3,16 For the Vizilite® Plus with TBlue, the
sensitivity was found to be a median of 85%, the
median specificity was 67%. The positive predictive value was 85% and the negative predictive
66

Figure 2: Tissue Appearance under the
Velscope® Vx

Source: Photographs used by permission. Taken at the
Dental Hygiene Research Center, Old Dominion University.

value was 83%.3 Therefore, the literature recommend the use of these devices may be useful as
opportunistic screening protocol with high risk
populations, where the pretest probability of oral
cancer is above 10%.10
This study supports the need for more research using new technologies. According to a
systematic review conducted by Kujan et al, no
evidence exists to suggest that other methods
of screening, toluidine blue, fluorescence imaging or brush biopsy, are effective as a diagnostic tool.10,12 VELscope® Vx is of particular interest
because there are limited studies examining the
effectiveness of the VELscope® Vx as an oral cancer screening tool in high risk populations. Unlike
other technologies, the device has minimal contraindications; per manufacturer’s instructions,
individuals taking medications that cause photosensitivity or predisposed to photosensitivity are
contraindicated for use of the VELscope® Vx because of the blue-white fluorescent light emitted
by the device.10
High risk populations include those who smoke
tobacco - smoking has been firmly established
as a direct causal link to oral cancer.17 The risk
of oral and oropharyngeal cancer increases with
regular alcohol consumption.17 The Healthy People 2020 report identified tobacco and alcohol
consumption as priorities for the prevention of
cancer.6 According to the American Cancer Society, 7 out of 10 oral cancer patients are heavy
drinkers.18 Since tobacco is one of the most common modifiable known risk factor of oral cancer,
cigarette smokers were chosen in this study as
the target population.
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Methods and Materials

A convenience sample of 30 cigarette smokers
or dual addiction (cigarette and hookah) smokers from the state of Virginia, Hampton Roads
area (Norfolk, Virginia Beach, and Chesapeake)
were recruited. Recruitment flyers were distributed electronically through the university faculty
and staff email announcement. Recruitment flyers
were also posted at various locations in the local
community.
The inclusion criteria included participants 18
years of age or older and people who smoke cigarettes only or in combination with other type of
tobacco use (hookah smoking). People who used
other forms of smoking habits (without cigarette
smoking) and individuals who were photosensitive were excluded from participation. Data collection took place on the campus of Old Dominion
University, Norfolk, Virginia and at 3 local senior
citizens nursing homes. Written informed consent
was obtained from each participant. Translators
trained in medical and dental terminology were
made available to individuals with limited English
proficiency.
Prior to data collection, the study was approved
by Old Dominion University institutional review
board. All participants completed a health information and medical history form. Demographic
data included age, gender and ethnicity/race. The
health history included questions to determine risk
for oral cancer to include history of cancer or cancer treatments, HPV infection and current medications. Smoking and alcohol habits were calculated
according to the frequency of tobacco and alcohol
use: the number of cigarettes/packs, the number
of times smoking hookah and the number of alcohol drinks consumed were calculated per day, per
week or per month. The duration of smoking in
years was also collected. At the completion of the
study, all participants received recommendations
regarding tobacco cessation and information on
the two examinations performed.
Each participant received both a visual and
tactile intraoral examination and a VELscope® Vx
examination to assess oral potentially malignant
lesions. Two licensed dental hygienists served as
investigators - one investigator conducted the
visual and tactile intraoral examination and the
second examiner conducted the VELscope® Vx examination. The examination sequence was standardized for all study participants - visual and tactile intraoral examination was conducted first by
investigator A, while investigator B conducted the
VELscope® Vx examination second. All investigators were educated and trained on the use of the

VELscope® Vx and the interpretation of findings
by a professional expert from LED Dental Inc, the
manufacturer of the VELscope® Vx. Investigators
also viewed a video tutorial on the proper use of
VELscope® Vx technology and how to interpret
findings. Because one examiner conducted each
type of examination, no inter-rater calibration was
necessary during the study. However, intra-rater
reliability was measured for each investigator using test-retest reliability.
Clinical findings were recorded using 6 data collection forms - 3 for visual and tactile intraoral
examination and 3 for the VELscope® Vx examination. Examination sequences were standardized
according to size, shape, color and texture of the
lesion. The sequence of the visual and tactile intraoral examination included bi-digital evaluation
of the lips, labial mucosa, right and left buccal
mucosa, visual inspection of the gingiva, bi-digital
palpation and visual inspection of the dorsal, ventral and lateral sides of the tongue, digital palpation of the floor of the mouth, visual inspection
and digital palpation of the hard palate, visual inspection of the visible portion of the soft palate,
and visual inspection of the oropharynx and uvula.
The VELscope® Vx examination followed the same
sequence without palpation.
Statistical Analysis
To determine demographic and medical health
risk behaviors in individuals who smoke tobacco,
t-test were measured. This test analyzed the significant difference between cigarette smokers and
dual addiction smokers by comparing the number
of cigarettes smoked per day, number of alcoholic
drinks consumed per month and length of time
smoking per year. The significance level was set
at 0.05.

Results
Thirty participants with a mean age of 42 years
were enrolled. Seventeen participants were cigarettes smokers and 13 participants reported dual
addiction (Table III). Cigarette smokers consisted
of 76.5% males (n=13) and 23.5% females (n=4).
For the dual addiction smokers, 77% were males
(n=10) and 23% (n=3) were females. Fifteen participants identified their ethnicity as Asian, 10 Caucasian, 3 African-American, 1 Hispanic and 1 Native American (Table III).
In participants who smoked cigarettes, the average length of time smoking was 14.1 years,
whereas the average length of time smoking for
dual addiction smokers was 5 years (Table IV).
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Table III: Demographics
Smoking Habit

Ethnicity

Age

Gender

AA

A

H

NA

C

19 to 34

>34

Male

Female

Cigarette smoking
n=17

2

8

0

0

7

11

6

13

4

Dual Addiction
n=13

1

7

1

1

3

13

0

10

3

Total
n=30

3

15

1

1

10

24

6

23

7

Key: AA=African American; A=Asian; H=Hispanic/Latino; NA=Native American; C=Caucasian
Dual Addiction=Cigarette + hookah smoking

Table IV: Health Determinants
Smoking
Habit
Cigarette
Smoking
n=17
Dual Addiction
n=13

Length of Time Smoking
(Years)

Number of Cigarettes Smoked
per day

Number of Alcoholic Drinks
per month

Mean + SE

p-value

Mean + SE

p-value

Mean + SE

p-value

14.1 + 3.11

0.005

13.2 + 2.56

-

5 + 1.79

-

5 + 0.89

0.005

14.5 + 2.92

-

13.9 + 7.63

-

Key: Dual Addiction= Cigarette + hookah smoking

The number of alcohol drinks consumed per month
for tobacco cigarette smokers was an average of
5 drinks. For dual addiction smokers, the average
was 13.9 drinks per month. The number of cigarettes per day for tobacco cigarettes only smokers
was an average of 13.2 cigarettes, whereas dual
addiction smokers reported an average of 14.5 cigarettes per day (Table IV). Results demonstrated
a statistically significant difference in the average
length of time smoking (in years) between the cigarettes smokers (14.1 years) and the dual addiction smokers (5 years).
Results showed there was no statistically significant difference between cigarette smokers and
dual addiction smokers in the average number of
alcoholic drinks per month (5 for cigarette smokers
and 13.9 for dual addiction). The average number
of cigarettes smoked per day did not show a statistically significant difference between the 2 groups
(13.2 for cigarette smokers and 14.5 for dual addiction) (Table IV).
There were no statistically significant differences
in the oral potentially malignant lesions detected
in cigarette or dual addiction smokers by the VELscope® Vx when compared to visual and tactile intraoral examination. No lesions were identified in
either group; therefore, results showed no differ68

ences between findings in either group. Although
the study protocol included taking intraoral photographs and referral to Eastern Virginia Medical
School for biopsy, no lesions were detected using
either type of examination; therefore, no intraoral
photographs or referrals were made.

Discussion
This study was conducted to determine if the
VELscope® Vx examination lead to improved detection of early stage lesions in submucosal tissues. While results of the 2 examination types
indicated no statistical difference, the majority
of participants reported 1 or more high risk behaviors for oral cancer. Demographic information gathered supports current literature on high
risk populations and an increase in the number
of younger populations who become habitual
smokers and also developing alcohol addiction
and dual-addiction smoking habits (specifically
those who smoke both cigarettes and hookah).19
All participants in this study presented 1 or more
health risk behaviors, or factors for developing
potentially malignant oral lesions.
This pilot study enrolled a small sample size
and results should be interpreted within that context. Mostly males were enrolled in this study,
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and less than one-third were females.17,20 Although the risk of oral cancer is increasing in
females, the research suggest overall males account for the majority of smokers.17 Participants
who consume alcohol in combination to smoking
have an added risk of oral cancer; 7 out of 10
oral cancer patients are heavy drinkers, according to the American Cancer Society.18 The literature identifies black populations as a high risk
racial group who smoke cigarettes.17,20 In this
very specific group population, Asians were the
majority of cigarette and dual addiction smokers.
The outcome of this study may have also been
influenced by a short observational period. Patient recruitment efforts were limited to a 3
month time period, contributing to a small nonrepresentative sample size of 30 subjects. Both
examination types were conducted in 1 appointment. This research study was limited to 1 year;
this did not allow time for scheduling periodic
oral cancer screening appointments to observe
any tissue changes. Limited funding and time
impeded the development of a cohort study to
investigate changes or alterations in the oral soft
tissues throughout a long period of time in high
risk populations.
The sample size used in this study was small
and therefore limited the results. The age range of
the majority of the sample was between 19 to 34
years, which indicates a young lower risk population. Almost two-thirds of the cigarette smokers
enrolled were under 34 years old and none of the
dual addiction smokers were above 34 years old.
The research identifies adults above 55 years old
as the highest risk age group.17,20 In this study,
13 of the 30 participants recorded dual addiction. The literature indicates hookah smoking is
becoming a trend within adolescents and young
adults,19 and this study supports that fact.
The lack of concern and education about oral
cancer may have had an influence on the outcomes and participation of this study. Research
suggests that the level of cancer concern ranges
from low to moderate in general and high risk
populations.21 There are no consistent findings
concerning whether cancer worry in high-risk
populations exceeds that for the general population.21 Overall, there is a lack of education on the
importance of oral cancer screening. Paulis suggests dental hygienists have an important role in
educating their patients regarding routine comprehensive intraoral and extraoral examination
of the head and neck area for oral cancer early
detection.22

The VELscope® Vx was initially approved by the
FDA in 2006 to “enhance the identification and
visualization of oral mucosal abnormalities that
may not be apparent or visible to the naked eye,
such as oral cancer or premalignant dysplasia.”14
The results of the present study did not show a
significant difference between the VELscope® Vx
examination and the visual and tactile intraoral
examination, thus supporting the importance of
the thorough traditional intraoral and extraoral
examination. The lack of the extraoral examination and the comprehensive palpatory examination of the head and neck and may have had
an influence on the outcomes. The VELscope®
Vx technology is an optical device that is only
used intraorally; its limitation includes the lack
of comprehensive soft tissue palpatory examination. This emphasizes the continued need for a
thorough traditional visual and palpatory intraoral and extraoral examination of the head and
neck, as well as the thyroid area.
Future studies should include a cohort research
study design that includes a broader spectrum of
high risk groups. For example, the inclusion criteria may include individuals having one or more
oral cancer high risk parameters. Recruitment
and time needed to conduct the research was
limited and future studies should also consider
longitudinal research design. This would allow
for a greater representation of high risk population. To observe the effectiveness of the VELscope® Vx in the detection of the early lesions at
subclinical levels, the cohort research study design should include scheduling periodic oral cancer screenings of the same participants every 6
months over a longer period of time that extends
to several years.

Conclusion
In this particular study, no lesions were identified in either group. The absence of findings supports the need of further high-quality research
evaluate very carefully the effectiveness of the
2 tested protocols in identifying the presence of
oral potentially malignant lesions. This study did
not produce statistically significant data to support or refute the use of the Velscope® Vx for
use as an exclusive oral cancer screening device
in cigarette smokers or those with dual addiction smoking habits. Therefore, the importance
of conventional oral cancer screening is still significant especially that it includes intraoral and
extraoral visual and tactile examination of the
head and neck areas. Then, based on the given
data, the use of adjunctive technologies, such as
the VELscope® Vx is kept as the clinician’s choice.
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Since the early diagnosis of oral cancer is the
key for better prognosis and higher survival rates,
more efforts should be made to enhance the effectiveness of the current technology-based adjunctive devices, including the VELscope® Vx, as
oral cancer screening tools.
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